Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pat Mccutcheon Insider Profile
4 Followers
Pat Mccutcheon, Director at MediPharm Labs, holds 15.63M shares in MediPharm Labs (Ticker: MEDIF). Most recently, Pat Mccutcheon Sold $500,000 shares of MediPharm Labs on Nov 24, 2021 for an estimated value of 119.21K.
Profitable Transactions
3 out of 5 Profitable Transactions
Average Return
+29.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Pat Mccutcheon's holdings
Insider Roles
Director
Roles that Pat Mccutcheon holds in companies
Most Profitable Insider Trade
The most profitable trade made by Pat Mccutcheon
Pat Mccutcheon's Trading History
List of latest transactions for each holding click on a transaction to see Pat Mccutcheon's performance on stock
You May Also Like
Pat Mccutcheon insider profile FAQ
What is the percentage of profitable transactions made by Pat Mccutcheon?
The percentage of profitable transactions made by Pat Mccutcheon is 60%.
What is the average return per transaction made by Pat Mccutcheon?
The average return per transaction made by Pat Mccutcheon is 29.20%.
What stocks does Pat Mccutcheon hold?
Pat Mccutcheon holds: MEDIF stocks.
What was Pat Mccutcheon’s latest transaction?
Pat Mccutcheon latest transaction was an Informative Sell of $119.21K.
What was Pat Mccutcheon's most profitable transaction?
Pat Mccutcheon’s most profitable transaction was an Informative Sell of MEDIF stock on June 29, 2021. The return on the trade was 84.10%.
What is Pat Mccutcheon's role in MediPharm Labs?
Pat Mccutcheon's role in MediPharm Labs is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.